12.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Erasca Inc Borsa (ERAS) Ultime notizie
Erasca (NASDAQ:ERAS) Trading Up 6.8%Should You Buy? - MarketBeat
Erasca stock reaches 52-week high at 12.48 USD - Investing.com
ERAS: Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors - TradingView
Erasca Sees Unusually High Options Volume (NASDAQ:ERAS) - MarketBeat
What sentiment indicators say about Erasca Inc. stock2025 Growth vs Value & Weekly Breakout Watchlists - mfd.ru
Erasca (NASDAQ:ERAS) Sets New 1-Year HighStill a Buy? - MarketBeat
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com - Investing.com South Africa
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - MSN
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline - simplywall.st
Erasca (NASDAQ:ERAS) Trading 6.4% HigherHere's What Happened - MarketBeat
Erasca to Present at Upcoming Conferences in February - The Manila Times
Erasca (ERAS) Price Target Increased by 60.94% to 10.51 - Nasdaq
Erasca (ERAS) Is Up 10.4% After $225M Follow-On Offering And RAS Pipeline UpdatesHas The Bull Case Changed? - Yahoo Finance
Erasca (NASDAQ:ERAS) Hits New 52-Week HighStill a Buy? - MarketBeat
Erasca stock hits 52-week high at $10.71 By Investing.com - Investing.com Nigeria
Erasca stock hits 52-week high at $10.71 - Investing.com India
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? - Barchart.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - MSN
Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT - Finviz
Mizuho Initiates Erasca (ERAS) With ‘Outperform’ Rating and $16 PT - Insider Monkey
11 Best Performing Stocks in the Last 12 Months - Insider Monkey
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models - Finviz
Erasca extends cash runway after upsized public offering - TipRanks
Erasca, Inc. Closes Upsized Public Offering - TradingView
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS? - simplywall.st
10 New Stocks on the Rise - Insider Monkey
Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress - Investing.com UK
Biotech Fundraising A Good Sign For Public Markets - Law360
Erasca stock price target raised to $15 from $11 at H.C. Wainwright - Investing.com
Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? - Benzinga
Morgan Stanley Raises Price Target on Erasca to $10 From $4, Keeps Equalweight Rating - marketscreener.com
Fundamentals Check: How does Erasca Inc perform in inflationary periods2025 Price Momentum & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Erasca completes $258.8 million public offering of common stock By Investing.com - Investing.com Australia
Erasca completes $258.8 million public offering of common stock - Investing.com India
Investor Mood: Should I average down on Erasca Inc stock2025 Major Catalysts & Stock Portfolio Risk Control - baoquankhu1.vn
Erasca Closes Public Offering - marketscreener.com
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):